Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration
Overview
- Phase
- Not Applicable
- Intervention
- Bevacizumab 1
- Conditions
- Exudative Age-related Macular Degeneration
- Sponsor
- Peking University People's Hospital
- Enrollment
- 210
- Locations
- 1
- Primary Endpoint
- EDTRS visual acuity score
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of neovascular Age-related macular degeneration
- •Signed informed consent
Exclusion Criteria
- •No other ocular fundus diseases
Arms & Interventions
Bevacizumab 1
Intervention: Bevacizumab 1
Bevacizumab 2
Intervention: Bevacizumab
Outcomes
Primary Outcomes
EDTRS visual acuity score
Time Frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week
EDTRS visual acuity score is assessed at each timepoint for every group
Secondary Outcomes
- macular thickness in OCT(0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week)